Contrasting Gyre Therapeutics (NASDAQ:GYRE) and Scienture (NASDAQ:SCNX)

Scienture (NASDAQ:SCNX) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Institutional & Insider Ownership

5.7% of Scienture shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 19.5% of Scienture shares are owned by company insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk and Volatility

Scienture has a beta of 3.34, suggesting that its share price is 234% more volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.89, suggesting that its share price is 89% more volatile than the S&P 500.

Profitability

This table compares Scienture and Gyre Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scienture	N/A	-53.51%	-42.47%
Gyre Therapeutics	-15.47%	-6.57%	-5.35%

Valuation & Earnings

This table compares Scienture and Gyre Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scienture	$430,000.00	343.66	-$41.51 million	($2.10)	-1.71
Gyre Therapeutics	$116.59 million	6.80	$5.03 million	($0.21)	-33.86

Gyre Therapeutics has higher revenue and earnings than Scienture. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Scienture and Gyre Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1	1	1	0	2.00
Gyre Therapeutics	2	0	1	0	1.67

Scienture presently has a consensus target price of $37.50, suggesting a potential upside of 941.96%. Gyre Therapeutics has a consensus target price of $16.00, suggesting a potential upside of 125.04%. Given Scienture’s stronger consensus rating and higher probable upside, research analysts clearly believe Scienture is more favorable than Gyre Therapeutics.

Summary

Scienture beats Gyre Therapeutics on 7 of the 13 factors compared between the two stocks.

About Scienture

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

About Gyre Therapeutics

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.